Navigation Links
Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation
Date:2/7/2008

SAN CARLOS, Calif., Feb. 7 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO) today announced that it will hold the following events in February:

BIO CEO & Investor Conference

February 13, 2008

11:45 a.m. ET

Dr. Ted W. Love, Chairman and CEO
http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=NUVO&item_id=1752425

Fourth Quarter and Year End 2007 Financial Results and Accomplishments

Conference Call & Webcast

February 27, 2008

4:30 p.m. ET (1:30 p.m. PT)

Dr. Ted W. Love, Chairman and CEO

Dr. Michael Levy, EVP, Research and Development

Lee Bendekgey, SVP, Finance and CFO

Dial in: 866-854-8095 domestic and 706-634-8567 international with

passcode 32403438

Replay: 800-642-1687 domestic and 706-645-9291 international with passcode

32403438, available through Wednesday, March 12, 2008

Webcast: This call is being webcast by Thomson/CCBN and can be accessed via Nuvelo's website at http://www.nuvelo.com. The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at http://www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (http://www.streetevents.com), a password-protected event management site.

Live audio webcasts of the events and presentations will also be available online via the Investor Relations portion of Nuvelo's website at http://www.nuvelo.com.

About Nuvelo

Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular disease, cancer and other debilitating medical conditions. Nuvelo's development pipeline includes alfimeprase, a direct acting fibrinolytic in Phase 2 clinical development for the treatment of thrombotic-related disorders including acute ischemic stroke and catheter occlusion; NU172, a direct thrombin inhibitor in Phase 1 development for use as a potential short-acting anticoagulant during medical or surgical procedures; and preclinical candidate NU206, a Wnt pathway modulator for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease. In addition, Nuvelo expects to continue its research programs in leukemia and lymphoma therapeutic antibodies and Wnt signaling pathway therapeutics to further expand its pipeline and create additional partnering and licensing opportunities.

Information about Nuvelo is available at our website at http://www.nuvelo.com or by phoning 650-517-8000.


'/>"/>
SOURCE Nuvelo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Nuvelo Announces Upcoming Conference Calls, Webcasts and Conference Participation
2. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
3. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
4. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
5. HEI, Inc. Announces Sale of RFID Division Assets
6. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
7. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
8. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
9. Brooke Franchise Corporation Announces Selected July Results
10. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... , ... January 23, 2017 , ... ... Assisted Living (IHCA/INCAL), will serve as a healthcare industry expert at the 2017 ... panel discussion, moderated by Inside Indiana Business host Gerry Dick, will feature an ...
(Date:1/23/2017)... , ... January 23, 2017 , ... "ProRandom is a set of camera tools that ... dynamic looks in Final Cut Pro X," said Christina Austin - CEO of Pixel Film ... two layers of text with video footage. ProRandom works by using a virtual camera ...
(Date:1/23/2017)... ... ... the Mill”: a story of love and redemption, hope and uncertainty as a girl ... , “The Inn at the Mill” is the creation of published author, Lois Kulp, who ... living in Berks County on Crow Hill. The inn, the mill and "Post ...
(Date:1/23/2017)... ... ... Infallible Characteristics of Christ”: a fascinating and entrancing novel exploring the gifts and ... author, Rev. Dr. Robert W. Thomas, the third of seven siblings. He was a ... pastor for over fifteen years. He is a graduate of N.C. College of Theology ...
(Date:1/22/2017)... ... ... "Photo Cloud allows FCPX users to add favorited photos to any drop ... Christina Austin - CEO of Pixel Film Studios. , To begin, select a ... include scenes with one, three, four or five focus points. There are five included ...
Breaking Medicine News(10 mins):
(Date:1/23/2017)... , Jan 23, 2017 NeuroVive ... NeuroVive has signed a preclinical collaboration agreement with the Children,s ... Marni J. Falk , M.D., a US key opinion leader ... ... CHOP will evaluate compounds from NeuroVive,s research program, NVP015, in ...
(Date:1/23/2017)... LONDON , Jan. 23, 2017 Just two weeks remain ... and intellectual property, gather in Central London to ... of its kind in the market, Parallel Trade 2017 . ... a preliminary list of attendees which is available to read in the ... ...
(Date:1/21/2017)... Research and Markets has announced the addition of the ... (Tumor, Clinical Chemistry, Microbiology, Esoteric), By Type of Lab (Hospital, ... HIV/AIDS etc.), Forecast to 2022" report to their offering. ... US ... clinical lab testing, which has evolved as a major source ...
Breaking Medicine Technology: